Novelix Pharmaceuticals Soars 4.99% Following Collaboration with Germany's GMBU e.V. for Astaxanthin Technology Transfer

Hyderabad, October 17, 2025: The share price of Novelix Pharmaceuticals Ltd (BSE: NOVELIX | 536565) rose 4.99% on Friday after the company’s announcement of signing a technology transfer deal with GMBU e.V., Germany. The alliance is to boost production of Astaxanthin, which is a powerful antioxidant used extensively in nutraceutical and pharma applications.

Haematococcus pluvialis astaxanthin is world famous for its antioxidant activity, utilized to fight oxidative stress while benefiting anti-inflammatory, cardiovascular, and neuroprotective well-being. It is used in nutraceuticals, cosmetics, as well as aquaculture feed, making it one of the world’s most popular molecules in the wellness industry.

Novelix Pharmaceuticals Limited, originally known as Trimurthi Limited, is a Hyderabad-based biopharmaceutical company dedicated to novel therapeutics, novel biologics, and nutraceutical research. The company maintains R&D and GMP-approved manufacturing facilities and caters to global markets with a focus on cost-effective and affordable healthcare options.

GMBU e.V. (Association for the Promotion of Medical, Biotechnology and Environmental Technologies) is a German non-profit research society founded in 1992 with subsidiaries based in Saxony-Anhalt, Thuringia, and Saxony. GMBU is a center for excellence in bioanalytics, bioprocess engineering, photonics, and nanotechnology with providing global technology cooperation.

Strategic Tie-Up for Scaling Up Astaxanthin

GMBU e.V. will supply proprietary technology, technical expertise, and assistance for the cultivation and large-scale production of Haematococcus pluvialis, a high-Astaxanthin yielding microalgae, in Novelix’s BTIC Park lab facilities at Genome Valley, Hyderabad. Novelix will make capital, infrastructural, and technological contributions, such as algal strains, media ingredients, and laboratory facilities and set up a GMP-certified production facility at its Techno Park site to produce Astaxanthin in bulk. The firm will target certain European, North American, and Indian markets for this venture.

Leadership Commentary

Dr. Enrico Ehrhardt, Molecular Biology Head at GMBU e.V., called the partnership a “milestone” that would “open new opportunities for shared innovation in biotechnology and medicine.” Mr. Gattu Gyan Prakash, Director of Novelix Pharmaceuticals Ltd, said, “We are excited to establish Astaxanthin production in India in association with GMBU e.V. The molecule has immense therapeutic potential, and this partnership is an excellent Indo–German example in biotechnology and life sciences.”.

Stock Snapshot

The stock of Novelix was at ₹44.15 as of 01:05 p.m. IST on 17 October 2025, up from the previous close of ₹42.05. The stock’s 52-week high is ₹52.79 and the low is ₹21.91, with the market cap standing at ₹57.11 crore and the P/E value standing at 100.34. EPS is ₹0.44 for the company.

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/24174e05-1125-4fa4-afa5-2ae340571d94.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations